Aclaris Therapeutics

Aclaris Therapeutics is a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases. The company's commercial product, ESKATA (hydrogen peroxide) topical solution, 40% (w/w), or ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. The company has acquired RHOFADE (oxymetazoline hydrochloride) cream, 1%, or RHOFADE, which includes a license to certain intellectual property for RHOFADE, from Allergan Sales, LLC. RHOFADE has been approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
  • TickerACRS
  • ISINUS00461U1051
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

MarketLine Department

Dermira, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Dermira, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Dermira, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highli...

Jonathan Moreland

InsiderInsights Daily Ratings Report: July 1, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Weekly Tables: May 18, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ValuEngine Rating and Forecast Report for ACRS

ResearchPool Subscriptions

Get the most out of your insights

Get in touch